Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBL7CW)

Drug Name
PRT-062607 Drug Info
Synonyms P-14276; P-505-15; Syk tyrosine kinase inhibitors (oral, cancers/inflammatory diseases/thrombosis), Portola
Cross-matching ID
PubChem CID
44462758
ChEBI ID
CHEMBL2177736
CAS Number
CAS 1370261-96-3
TTD Drug ID
D0R9IU

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Terpenoid backbone biosynthesis 2.23 0.00e+0 18/22 (81.82%) HMGCS1;FDPS;ACAT1;...
Steroid biosynthesis 2.22 0.00e+0 19/20 (95%) DHCR24;MSMO1;SQLE;...
Valine, leucine and isoleucine degradation 2.20 0.00e+0 42/48 (87.5%) HMGCS1;ACAA1;ACAT1;...
Biosynthesis of unsaturated fatty acids 2.10 0.00e+0 21/27 (77.78%) ELOVL6;ACAA1;FADS1;...
Glyoxylate and dicarboxylate metabolism 1.98 0.00e+0 23/30 (76.67%) SHMT1;ACAT1;ACAT2;...
Synthesis and degradation of ketone bodies 1.97 1.13e-3 9/10 (90%) HMGCS1;ACAT1;ACAT2;...
Butanoate metabolism 1.91 3.89e-3 23/28 (82.14%) HMGCS1;ACAT1;ACAT2;...
N-Glycan biosynthesis 1.89 6.81e-3 38/50 (76%) GANAB;DPM3;ST6GAL1;...
Fatty acid degradation 1.81 1.36e-2 40/43 (93.02%) ACAA1;ACAT1;ALDH2;...
Asthma -1.66 2.50e-2 25/31 (80.65%) HLA-DQB1;FCER1G;HLA-DPA1;...
Salmonella infection -1.67 2.36e-2 198/249 (79.52%) MAPK3;DYNLL1;HSP90AB1;...
Shigellosis -1.68 2.45e-2 180/246 (73.17%) MAPK3;PPID;PIK3CD;...
Relaxin signaling pathway -1.68 2.39e-2 114/129 (88.37%) TGFBR2;NRAS;COL3A1;...
Fluid shear stress and atherosclerosis -1.68 2.38e-2 123/139 (88.49%) ARHGEF2;HMOX1;ACTB;...
Graft-versus-host disease -1.69 2.37e-2 32/42 (76.19%) KIR2DL3;HLA-E;IL6;...
Phagosome -1.70 2.31e-2 118/152 (77.63%) ATP6V1C1;ATP6V1E1;ATP6V0E1;...
NF-kappa B signaling pathway -1.70 2.41e-2 90/104 (86.54%) PRKCB;TRAF6;BIRC2;...
Legionellosis -1.70 2.52e-2 51/57 (89.47%) VCP;EEF1A2;CASP1;...
Insulin secretion -1.70 2.57e-2 75/86 (87.21%) PCLO;KCNN1;INS;...
Epstein-Barr virus infection -1.71 2.57e-2 189/202 (93.56%) MAPK14;CD19;PSMC2;...
Synaptic vesicle cycle -1.75 1.73e-2 63/78 (80.77%) UNC13B;SLC1A7;ATP6V1D;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.75 1.83e-2 79/89 (88.76%) CD3E;MAPK3;PIK3CD;...
Viral myocarditis -1.76 1.78e-2 53/60 (88.33%) SGCB;CD80;ABL1;...
Viral protein interaction with cytokine and cytokine re... -1.77 1.65e-2 84/100 (84%) CXCR5;CXCL5;TNFRSF1A;...
Rheumatoid arthritis -1.80 1.05e-2 78/93 (83.87%) ATP6V1C1;ATP6V1E1;CD80;...
AGE-RAGE signaling pathway in diabetic complications -1.80 1.04e-2 97/100 (97%) PLCE1;MAPK3;PIK3CD;...
Chagas disease -1.80 1.12e-2 93/102 (91.18%) NFKB1;GNAQ;C1QB;...
Malaria -1.84 7.69e-3 44/50 (88%) GYPC;VCAM1;CD36;...
Hematopoietic cell lineage -1.85 7.19e-3 90/99 (90.91%) IL1A;CD5;ANPEP;...
Autoimmune thyroid disease -1.89 6.59e-3 46/53 (86.79%) FASLG;HLA-DOA;CD40;...
Allograft rejection -1.91 5.86e-3 32/38 (84.21%) FASLG;HLA-DOA;CD40;...
IL-17 signaling pathway -1.94 4.94e-3 84/94 (89.36%) NFKB1;CCL17;HSP90B1;...
Type I diabetes mellitus -1.95 5.65e-3 38/43 (88.37%) FASLG;PTPRN2;HLA-DOA;...
Th17 cell differentiation -1.96 4.39e-3 95/107 (88.79%) CD3E;MAPK3;HSP90AB1;...
Leishmaniasis -1.98 5.27e-3 67/77 (87.01%) PRKCB;TRAF6;NFKBIB;...
Inflammatory bowel disease -1.99 6.59e-3 58/65 (89.23%) IL18RAP;NOD2;NFKB1;...
Th1 and Th2 cell differentiation -2.02 4.39e-3 80/92 (86.96%) CD4;NFKBIB;IL2RA;...
Osteoclast differentiation -2.02 6.59e-3 117/127 (92.13%) LILRB4;TGFBR1;TRAF6;...
TNF signaling pathway -2.05 1.32e-2 103/112 (91.96%) BIRC2;NOD2;NFKB1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 4H, 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 24H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 4H, 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 4H, 24H
Mantle cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MINO CVCL_4965 Homo sapiens 0.01uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 3.33uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.11uM - 10uM 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H
Urinary bladder
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H